Dublin-headquartered Mallinckrodt is taking over smaller rival Endo and planning to list the combined firm on the New York Stock Exchange, the two drugmakers said Thursday. The new firm will have ...

Endo and Mallinckrodt, two drugmakers seeking to recover from opioid lawsuits and bankruptcies, are betting a combination will help. Investors took a dim view Thursday. Shares of Endo fell more ...

Peter Loftus is a reporter for The Wall Street Journal in Philadelphia covering the pharmaceutical and medical-device ...

Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official, Peter Marks, had been forced to resign, the most high-profile exit at the ...

DUBLIN, April 10, 2025 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmaceutical company, today announced that it will report its first quarter 2025 financial results on Tuesday ...

The prices for the first 10 prescription drugs it negotiated were still on average more than double, and in some cases five times, what drugmakers had agreed to in four other high-income countries ...

Last month, Endo entered into an agreement to merge with Mallinckrodt in a cash and stock transaction that values the combined pharmaceutical company at $6.7 billion. On April 1, according to ...

Biotech shares pressured after resignation S&P 500 biotech ETF down 4.9%, Moderna slumps 12.3% Marks' departure adds uncertainty March 31 (Reuters) - Shares of U.S. drugmakers fell on Monday after ...

TARIFFS ON MEDS? NOT YET — The U.S. stock market took a pounding Thursday, but drugmakers spent the day in quiet celebration. The deep-pocketed drug lobby that President Donald Trump once ...

Business may be picking up for locally-based drugmakers just a year after the local sector was showing declines. Employee headcount for the top seven pharmaceutical companies with offices in Orange ...

After a batch of much-anticipated reciprocal tariffs spared pharmaceuticals in early April, drugmakers, medtech companies, manufacturers and other outfits across the life sciences spectrum are ...

As U.S. drugmakers have released their proxy statements in recent weeks, several reported six-figure expenditures to protect their top execs. Last month, in divulging a $19.9 million pay package ...